VFA
SLS icon

Values First Advisors’s SELLAS Life Sciences SLS Stock Holding History

Values First Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15
Closed -$21 – 311
2023
Q1 		$21 Buy
+15
New +$37 ﹤0.01% 367

Other funds holding SLS

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EH
Equitable Holdings New York $16.7B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
PFG
Prosperity Financial Group San Ramon, California $323M AUM 35.79% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Values First Advisors's SLS Position: Q2 2023 in Review

Values First Advisors sold out of SELLAS Life Sciences (SLS) in Q2 2023, closing a stake of 15 shares — an estimated $21 sold.

Values First Advisors first reported a position in SLS in Q1 2023 and held it in 1 quarter. The position peaked at $21 in Q1 2023. 25 funds tracked by Wall St. Rank hold SLS as of Q2 2023.

  • Values First Advisors reported no remaining SELLAS Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Values First Advisors sold 15 SELLAS Life Sciences shares in Q2 2023, an estimated $21.
  • Values First Advisors first reported a position in SELLAS Life Sciences in Q1 2023 and held it in 1 quarter.
  • Values First Advisors's SELLAS Life Sciences position peaked at $21 in Q1 2023.
  • 25 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.